Galderma
CLICK HERE if you are a Consumer
Roll Over for Important Safety Information

BEFORE & AFTER PHOTOS

The proof is in the pictures—MetroGel® 1% delivers visible results*

These actual unretouched photos tell the Oracea® story better than words.

Individual Results May Vary.

The patients depicted on these "before and after" photographs were actual participants in the clinical trials for Oracea® studies 301 and 302.

Study 301:
Patient ID#: 301.115
Baseline After 16 weeks of treatment with Oracea®

This study was Phase III, parallel-group, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Oracea, in which patients received 40 mg of Oracea or a placebo for 16 weeks.

Study 302:
Patient ID#: 302.1009
Baseline After 16 weeks of treatment with Oracea®


Patient ID#: 302.4023
Baseline After 16 weeks of treatment with Oracea®


Patient ID#: 302.4030
Baseline After 16 weeks of treatment with Oracea®

This study was Phase III, parallel-group, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Oracea, in which patients received 40 mg of Oracea or a placebo for 16 weeks.

Reference:

1) Del Rosso JQ, Webster, GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802.



HELP YOUR PATIENTS
 FIND A DERMATOLOGIST
(Enter the first 3 digits of your zip code)

IMPORTANT SAFETY INFORMATION

METROGEL® (metronidazole) Gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. The most common adverse reactions that have been reported with the topical use of METROGEL® 1% are nasopharyngitis, upper respiratory tract infections and headaches, as well as dryness, scaling, itching, and stinging. Transient redness, metallic taste, tingling or numbness of extremities and nausea have also been reported with the topical use of metronidazole. METROGEL®1% therapy should be reevaluated if these symptoms occur. Caution should be used when prescribing metronidazole products for patients with blood dyscrasia, and patients using blood thinning agents such as coumarin or warfarin may experience prolonged prothrombin times. METROGEL® 1% is contraindicated in patients with a history of hypersensitivity to metronidazole or any other ingredient in the formulation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.